DBV Technologies (DBVT) Projected to Post Earnings on Thursday

DBV Technologies (NASDAQ:DBVT) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect DBV Technologies to post earnings of ($0.31) per share and revenue of $1.08 million for the quarter.

DBV Technologies Price Performance

DBV Technologies stock opened at $4.30 on Wednesday. The company’s 50 day simple moving average is $4.15 and its 200 day simple moving average is $3.81. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $9.09. The firm has a market capitalization of $88.45 million, a price-to-earnings ratio of -0.96 and a beta of 0.67.

Analysts Set New Price Targets

Several analysts have commented on the stock. JMP Securities restated a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th. StockNews.com assumed coverage on shares of DBV Technologies in a report on Wednesday, February 26th. They set a “hold” rating on the stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.